본문 바로가기
KERD
논문KCI 등재

Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases

Kim Hyunsoo|Takegahara Noriko|Choi Yongwon
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 264-272|DOI 10.1038/s12276-024-01157-7

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Osteoclasts are the principal cells that efficiently resorb bone. Numerous studies have attempted to reveal the molecular pathways leading to the differentiation and activation of osteoclasts to improve the treatment and prevention of osteoporosis and other bone-destructive diseases. While the cumulative knowledge of osteoclast regulatory molecules, such as receptor activator of nuclear factor-kB ligand (RANKL) and nuclear factor of activated T cells 1 (NFATc1), contributes to the understanding of the developmental progression of osteoclasts, little is known about how the discrete steps of osteoclastogenesis modify osteoclast status but not the absolute number of osteoclasts. The regulatory mechanisms involved in osteoclast maturation but not those involved in differentiation deserve special attention due to their potential use in establishing a more effective treatment strategy: targeting late-phase differentiation while preserving coupled bone formation. Recent studies have shed light on the molecules that govern late-phase osteoclast differentiation and maturation, as well as the metabolic changes needed to adapt to shifting metabolic demands. This review outlines the current understanding of the regulation of osteoclast differentiation, as well as osteoclast metabolic adaptation as a differentiation control mechanism. Additionally, this review introduces molecules that regulate the late-phase osteoclast differentiation and thus minimally impact coupled bone formation.

Abstract

Osteoclasts are the principal cells that efficiently resorb bone. Numerous studies have attempted to reveal the molecular pathways leading to the differentiation and activation of osteoclasts to improve the treatment and prevention of osteoporosis and other bone-destructive diseases. While the cumulative knowledge of osteoclast regulatory molecules, such as receptor activator of nuclear factor-kB ligand (RANKL) and nuclear factor of activated T cells 1 (NFATc1), contributes to the understanding of the developmental progression of osteoclasts, little is known about how the discrete steps of osteoclastogenesis modify osteoclast status but not the absolute number of osteoclasts. The regulatory mechanisms involved in osteoclast maturation but not those involved in differentiation deserve special attention due to their potential use in establishing a more effective treatment strategy: targeting late-phase differentiation while preserving coupled bone formation. Recent studies have shed light on the molecules that govern late-phase osteoclast differentiation and maturation, as well as the metabolic changes needed to adapt to shifting metabolic demands. This review outlines the current understanding of the regulation of osteoclast differentiation, as well as osteoclast metabolic adaptation as a differentiation control mechanism. Additionally, this review introduces molecules that regulate the late-phase osteoclast differentiation and thus minimally impact coupled bone formation.

참고문헌 (147)

  1. Sims, N. A., "Osteoclasts provide coupling signals to osteoblast lineage cells through multiple mechanisms", Annu. Rev. Physiol, 82, pp.507~529 (2020)
  2. Bolamperti, S., "Bone remodeling : an operational pro cess ensuring survival and bone mechanical competence", Bone Res, 10, pp.48~ (2022)
  3. Tang, Y., "TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation", Nat. Med, 15, pp.757~765 (2009)
  4. Xian, L., "Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells", Nat. Med, 18, pp.1095~1101 (2012)
  5. Centrella, M., "Local regulators of skeletal growth : a perspective", Endocr. Rev, 6, pp.544~551 (1985)
  6. Hock, J. M., "Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts", Endocrinology, 134, pp.1423~1428 (1994)
  7. Sanchez-Fernandez, M. A., "Osteoclasts control osteoblast chemotaxis via PDGF-BB", PDGF receptor beta signaling, 2008, pp.3, e3537~
  8. Mitlak, B. H., "The effect of systemically administered PDGF-BB on the rodent skeleton", J. Bone Miner. Res, 11, pp.238~247 (1996)
  9. Oreffo, R. O., "Activation of the bone-derived latent TGF beta complex by isolated osteoclasts", Biochem. Biophys. Res. Commun, 158, pp.817~823 (1989)
  10. Fiedler, J., "BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells", J. Cell. Biochem, 87, pp.305~312 (2002)
  11. Rickard, D. J., "Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2", Dev. Biol, 161, pp.218~228 (1994)
  12. Robey, P. G., "Osteoblasts synthesize and respond to transforming growth factor-type beta(TGF-beta)in vitro", J. Cell. Biol, 105, pp.457~463 (1987)
  13. Hock, J. M., "Transforming growth factor-beta stimu lates bone matrix apposition and bone cell replication in cultured fetal rat calvariae", Endocrinology, 126, pp.421~426 (1990)
  14. Pederson, L., "Regulation of bone formation by osteoclasts involves Wnt", BMP signaling and the chemokine sphingosine-1-phosphate, 2008, pp.105, 20764~20769
  15. Walker, E. C., "Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling", J. Bone Miner. Res, 23, pp.2025~2032 (2008)
  16. Takeshita, S., "Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation", J. Clin. Investig, 123, pp.3914~3924 (2013)
  17. Garimella, R., "Expression and synthesis of bone morphogenetic proteins by osteoclasts : a possible path to anabolic bone remodeling", J. Histochem. Cyto chem, 56, pp.569~577 (2008)
  18. Matsuoka, K., "Osteoclast-derived complement component 3a stimulates osteoblast differentiation", J. Bone Miner. Res, 29, pp.1522~1530 (2014)
  19. Kim, B. J., "Osteoclast-secreted SLIT3 coordinates bone resorption and for mation", J. Clin. Investig, 128, pp.1429~1441 (2018)
  20. Ota, K., "Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors", Bone, 57, pp.68~75 (2013)
  21. Zhao, C., "Bidirectional ephrinB2-EphB4 signaling controls bone home ostasis", Cell Metab, 4, pp.111~121 (2006)
  22. Negishi-Koga, T., "Suppression of bone formation by osteoclastic expression of semaphorin 4D", Nat. Med, 17, pp.1473~1480 (2011)
  23. Tonna, S., "EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis", FASEB J, 28, pp.4482~4496 (2014)
  24. Ikebuchi, Y., "Coupling of bone resorption and formation by RANKL reverse signalling", Nature, 561, pp.195~200 (2018)
  25. Li, D., "Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation", Nat. Commun, 7, pp.10872~ (2016)
  26. Reszka, A. A., "Bisphosphonate mechanism of action", Curr. Rheu matol. Rep, 5, pp.65~74 (2003)
  27. Drake, M. T., "Bisphosphonates: mechanism of action and role in clinical practice", Mayo Clin. Proc, 83, pp.1032~1045 (2008)
  28. Takegahara, N., "RANKL biology", Bone, 159, pp.116353~ (2022)
  29. Miyazaki, T., "A review of denosumab for the treatment of osteoporosis", Patient Prefer. Adher, 8, pp.463~471 (2014)
  30. Lacey, D. L., "Bench to bedside : elucidation of the OPG-RANK-RANKL pathway and the development of denosumab", Nat. Rev. Drug Discov, 11, pp.401~419 (2012)
  31. Seeman, E., "Antiresorptive and anabolic agents in the prevention and reversal of bone fragility", Nat. Rev. Rheumatol, 15, pp.225~236 (2019)
  32. Sims, N. A., "Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and oda nacatib", Curr. Osteoporos. Rep, 12, pp.98~106 (2014)
  33. Dou, C., "Graphene-based MicroRNA transfection blocks preosteoclast fusion to increase bone formation and vascularization", Adv. Sci, 5, pp.1700578~ (2018)
  34. Chiu, Y. H., "Dendritic cell-specific transmembrane protein(DC-STAMP)regulates osteoclast differentiation via the Ca(2+)", NFATc1 Axis, 2017, pp.232, 2538~2549
  35. Witwicka, H., "Studies of OC-STAMP in osteoclast fusion : a new knockout mouse model, rescue of cell fusion, and transmembrane topology", PLoS One, 10, pp.e0128275~ (2015)
  36. Miyamoto, H., "Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells", J. Bone Miner. Res, 27, pp.1289~1297 (2012)
  37. Yang, M., "Osteoclast stimulatory transmembrane protein(OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation", J. Cell. Physiol, 215, pp.497~505 (2008)
  38. Yagi, M., "DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells", J. Exp. Med, 202, pp.345~351 (2005)
  39. Kodama, J., "Osteoclast multinucleation : review of current literature", Int. J. Mol. Sci, 21, pp.5685~ (2020)
  40. Ross, F. P., "M-CSF, c-Fms, and signaling in osteoclasts and their precursors", Ann. N. Y Acad. Sci, 1068, pp.110~116 (2006)
  41. Hamilton, J. A., "Colony-stimulating factors in inflammation and autoimmunity", Nat. Rev. Immunol, 8, pp.533~544 (2008)
  42. Ross, F. P., "alphavbeta3 and macrophage colony-stimulating factor : partners in osteoclast biology", Immunol. Rev, 208, pp.88~105 (2005)
  43. Pixley, F. J., "CSF-1 regulation of the wandering macrophage:complexity in action", Trends Cell Biol, 14, pp.628~638 (2004)
  44. Arai, F., "Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB(RANK)receptors", J. Exp. Med, 190, pp.1741~1754 (1999)
  45. Nakashima, T., "Evidence for osteocyte regulation of bone homeostasis through RANKL expression", Nat. Med, 17, pp.1231~1234 (2011)
  46. Xiong, J., "Matrix-embedded cells control osteoclast formation", Nat. Med, 17, pp.1235~1241 (2011)
  47. Boyce, B. F., "Advances in the regulation of osteoclasts and osteoclast functions", J. Dent. Res, 92, pp.860~867 (2013)
  48. Kanazawa, K., "Self-assembled RANK induces osteoclastogenesis ligand-independently", J. Bone Miner. Res, 20, pp.2053~2060 (2005)
  49. Wong, B. R., "The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor", J. Biol. Chem, 273, pp.28355~28359 (1998)
  50. Kobayashi, N., "Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis", EMBO J, 20, pp.1271~1280 (2001)
  51. Abu-Amer, Y., "NF-kappaB signaling and bone resorption", Osteoporos. Int, 24, pp.2377~2386 (2013)
  52. Franzoso, G., "Requirement for NF-kappaB in osteoclast and B-cell devel opment", Genes Dev, 11, pp.3482~3496 (1997)
  53. Matsuo, K., "Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation", Nat. Genet, 24, pp.184~187 (2000)
  54. Wagner, E. F., "Functions of AP1 (Fos", Jun) in bone development, 2002, pp.61, ii40~ii42
  55. Grigoriadis, A. E., "c-Fos : a key regulator of osteoclast-macrophage lineage determination and bone remodeling", Science, 266, pp.443~448 (1994)
  56. Kim, K., "NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein(DC-STAMP)", Mol. Endocrinol, 22, pp.176~185 (2008)
  57. Ishida, N., "Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator", J. Biol. Chem, 277, pp.41147~41156 (2002)
  58. Takayanagi, H., "Induction and activation of the transcription factor NFATc1(NFAT2)integrate RANKL signaling in terminal differentiation of osteoclasts", Dev. Cell, 3, pp.889~901 (2002)
  59. Asagiri, M., "Autoamplification of NFATc1 expression determines its essential role in bone homeostasis", J. Exp. Med, 202, pp.1261~1269 (2005)
  60. Yamashita, T., "NF-kappaB p50 and p52 regulate receptor activator of NF kappaB ligand(RANKL)and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1", J. Biol. Chem, 282, pp.18245~18253 (2007)
  61. Maeda, K., "Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis", Nat. Med, 18, pp.405~412 (2012)
  62. Koga, T., "Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis", Nature, 428, pp.758~763 (2004)
  63. Kim, N., "A novel member of the leukocyte receptor complex regulates osteoclast differentiation", J. Exp. Med, 195, pp.201~209 (2002)
  64. Humphrey, M. B., "TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function", J. Bone Miner. Res, 21, pp.237~245 (2006)
  65. Cella, M., "Impaired differentiation of osteoclasts in TREM-2-deficient indi viduals", J. Exp. Med, 198, pp.645~651 (2003)
  66. Shinohara, M., "Tyrosine kinases Btk and Tec regulate osteoclast differ entiation by linking RANK and ITAM signals", Cell, 132, pp.794~806 (2008)
  67. Walsh, M. C., "Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond", Front. Immunol, 5, pp.511~ (2014)
  68. Kim, K., "MafB negatively regulates RANKL-mediated osteoclast differ entiation", Blood, 109, pp.3253~3259 (2007)
  69. Zhao, B., "Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis", Nat. Med, 15, pp.1066~1071 (2009)
  70. Miyauchi, Y., "The Blimp1-Bcl6 axis is critical to regulate osteoclast differ entiation and bone homeostasis", J. Exp. Med, 207, pp.751~762 (2010)
  71. Park, S. J., "Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation", Sci. Rep, 6, pp.26186~ (2016)
  72. Takegahara, N., "Encyclopedia of Bone Biology Vol. 1", pp.221~235 (2020), Academic Press
  73. Takegahara, N., "Involvement of receptor activator of nuclear Factor-kappaB Ligand(RANKL)-induced incomplete cytokinesis in the polyploidization of osteoclasts", J. Biol. Chem, 291, pp.3439~3454 (2016)
  74. Kikuta, J., "Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases", Rheumatology, 52, pp.226~234 (2013)
  75. Pereira, M., "Common signalling pathways in macrophage and osteoclast multinucleation", J. Cell. Sci, 131, pp.jcs216267~ (2018)
  76. Khan, U. A., "CCL2and CCR2 are essential for the formation of osteoclasts and foreign body giant cells", J. Cell. Biochem, 117, pp.382~389 (2016)
  77. Sul, O. J., "Absence of MCP-1 leads to elevated bone mass via impaired actin ring formation", J. Cell. Physiol, 227, pp.1619~1627 (2012)
  78. McHugh, K. P., "Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts", J. Clin. Investig, 105, pp.433~440 (2000)
  79. Fiorino, C., "E-cadherin is important for cell differentiation during osteoclastogenesis", Bone, 86, pp.106~118 (2016)
  80. Kim, H., "IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95", Bone Res, 8, pp.5~ (2020)
  81. Kim, H., "Protocadherin-7 regulates osteoclast differ entiation through intracellular SET-binding domain-mediated RhoA and Rac1activation", Int. J. Mol. Sci, 22, pp.13117~ (2021)
  82. Kukita, T., "RANKL-induced DC-STAMP is essential for osteoclastogenesis", J. Exp. Med, 200, pp.941~946 (2004)
  83. Lee, S. H., "v-ATPase V0 subunit d2-deficient mice exhibit impaired osteo clast fusion and increased bone formation", Nat. Med, 12, pp.1403~1409 (2006)
  84. Feng, X., "Osteoclasts : new Insights", Bone Res, 1, pp.11~26 (2013)
  85. Weivoda, M. M., "The roles of small GTPases in osteoclast biology", Orthop. Muscular Syst, 3, pp.1000161~ (2014)
  86. Croke, M., "Rac deletion in osteoclasts causes severe osteopetrosis", J. Cell. Sci, 124, pp.3811~3821 (2011)
  87. Razzouk, S., "Rac-GTPase, osteoclast cytoskeleton and bone resorption", Eur. J. Cell Biol, 78, pp.249~255 (1999)
  88. Duong, L. T., "Integrins and signaling in osteoclast function", Matrix Biol, 19, pp.97~105 (2000)
  89. Zou, W., "Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption", J. Cell. Biol, 176, pp.877~888 (2007)
  90. Faccio, R., "Vav3 regulates osteoclast function and bone mass", Nat. Med, 11, pp.284~290 (2005)
  91. Novack, D. V., "The osteoclast: friend or foe?", Annu Rev. Pathol, 3, pp.457~484 (2008)
  92. Boyce, B. F., "Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice", J. Clin. Investig, 90, pp.1622~1627 (1992)
  93. Miyazaki, T., "Src kinase activity is essential for osteoclast function", J. Biol. Chem, 279, pp.17660~17666 (2004)
  94. Vacher, J., "Ostm1 from mouse to human : insights into osteoclast maturation", Int. J. Mol. Sci, 21, pp.5600~ (2020)
  95. Neutzsky-Wulff, A. V., "Severe developmental bone phenotype in ClC-7deficient mice", Dev. Biol, 344, pp.1001~1010 (2010)
  96. Kornak, U., "Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis", Hum. Mol. Genet, 9, pp.2059~2063 (2000)
  97. Kornak, U., "Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man", Cell, 104, pp.205~215 (2001)
  98. Teitelbaum, S. L., "Genetic regulation of osteoclast development and function", Nat. Rev. Genet, 4, pp.638~649 (2003)
  99. Takayanagi, H., "Osteoclast differentiation and activation", Clin. Calcium, 17, pp.484~492 (2007)
  100. Roy, M., "Rab GTPases in osteoclastic bone resorption and autophagy", Int. J. Mol. Sci, 21, pp.7655~ (2020)
  101. Zhao, H., "Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion", Dev. Cell, 14, pp.914~925 (2008)
  102. DeSelm, C. J., "Autophagy proteins regulate the secretory component of osteoclastic bone resorption", Dev. Cell, 21, pp.966~974 (2011)
  103. Sobacchi, C., "Osteopetrosis : genetics, treatment and new insights into osteoclast function", Nat. Rev. Endo crinol, 9, pp.522~536 (2013)
  104. Nesbitt, S. A., "Trafficking of matrix collagens through bone resorbing osteoclasts", Science, 276, pp.266~269 (1997)
  105. Salo, J., "Removal of osteoclast bone resorption products by transcytosis", Science, 276, pp.270~273 (1997)
  106. Indo, Y., "Metabolic regulation of osteoclast differentiation and function", J. Bone Miner. Res, 28, pp.2392~2399 (2013)
  107. Ishii, K. A., "Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation", Nat. Med, 15, pp.259~266 (2009)
  108. Lemma, S., "Energy metabolism in osteoclast formation and activity", Int. J. Biochem. Cell Biol, 79, pp.168~180 (2016)
  109. Jeng, J. Y., "Maintenance of mitochondrial DNA copy number and expres sion are essential for preservation of mitochondrial function and cell growth", J. Cell. Biochem, 103, pp.347~357 (2008)
  110. Larsson, N. G., "Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice", Nat. Genet, 18, pp.231~236 (1998)
  111. Wang, J., "Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression", Nat. Genet, 21, pp.133~137 (1999)
  112. Li, H., "Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy", Proc. Natl. Acad. Sci. USA, 97, pp.3467~3472 (2000)
  113. Miyazaki, T., "Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption", J. Biol. Chem, 287, pp.37808~37823 (2012)
  114. Wei, W., "PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss", Cell Metab, 11, pp.503~516 (2010)
  115. Nishikawa, K., "DNA methyltransferase 3a regulates osteoclast differentia tion by coupling to an S-adenosylmethionine-producing metabolic pathway", Nat. Med, 21, pp.281~287 (2015)
  116. Bae, S., "MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha", J. Clin. Investig, 127, pp.2555~2568 (2017)
  117. Jin, Z., "Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization", Cell Metab, 20, pp.483~498 (2014)
  118. Christofk, H. R., "Pyruvate kinase M2 is a phosphotyrosine-binding protein", Nature, 452, pp.181~186 (2008)
  119. Liberti, M. V., "The warburg effect: how does it benefit cancer cells?", Trends Biochem. Sci, 41, pp.211~218 (2016)
  120. Vander Heiden, M. G., "Understanding the Warburg Effect : the metabolic requirements of cell proliferation", Science, 324, pp.1029~1033 (2009)
  121. Ahn, H., "Accelerated lactate dehydrogenase activity potentiates osteo clastogenesis via NFATc1 signaling", PLoS One, 11, pp.e0153886~ (2016)
  122. Kim, J. M., "Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL-stimulated osteo clast differentiation", Cell Physiol. Biochem, 20, pp.935~946 (2007)
  123. Kim, H., "IgSF11-mediated phosphorylation of pyruvate kinase M2 regulates osteoclast differentiation and prevents pathological bone loss", Bone Res, 11, pp.17~ (2023)
  124. Murata, K., "Hypoxia-Sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis", Immunity, 47, pp.66~79 (2017)
  125. Hitosugi, T., "Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth", Sci. Signal, 2, pp.ra73~ (2009)
  126. Ward, P. S., "Metabolic reprogramming : a cancer hallmark even warburg did not anticipate", Cancer Cell, 21, pp.297~308 (2012)
  127. Nishikawa, K., "Osteoclasts adapt to physioxia perturbation through DNA demethylation", EMBO Rep, 22, pp.e53035~ (2021)
  128. Utting, J. C., "Hypoxia stimulates osteoclast formation from human peripheral blood", Cell Biochem. Funct, 28, pp.374~380 (2010)
  129. Knowles, H. J., "Acute hypoxia and osteoclast activity : a bal ance between enhanced resorption and increased apoptosis", J. Pathol, 218, pp.256~264 (2009)
  130. Knowles, H. J., "Hypoxia inducible factor regulates osteoclast-mediated bone resorption : role of angiopoietin-like 4", FASEB J, 24, pp.4648~4659 (2010)
  131. Morten, K. J., "Differential regulation of HIF-mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts", J. Pathol, 229, pp.755~764 (2013)
  132. Knowles, H. J., "Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte osteoclast differentiation via induction of VEGF", J. Pathol, 215, pp.56~66 (2008)
  133. Miyauchi, Y., "HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis", Proc. Natl. Acad. Sci. USA, 110, pp.16568~16573 (2013)
  134. Devignes, C. S., "Amino acid metabolism in skeletal cells", Bone Rep, 17, pp.101620~ (2022)
  135. DeBerardinis, R. J., "The biology of cancer : metabolic reprogramming fuels cell growth and proliferation", Cell Metab, 7, pp.11~20 (2008)
  136. Brunner, J. S., "Environmental arginine controls multinuclear giant cell metabolism and formation", Nat. Commun, 11, pp.431~ (2020)
  137. Brosnan, J. T., "Branched-chain amino acids: enzyme and sub strate regulation", J. Nutr, 136, pp.207S~211S (2006)
  138. Pereira, M., "A trans-eQTL network regulates osteoclast multinucleation and bone mass", Elife, 9, pp.e55549~ (2020)
  139. Go, M., "BCAT1 promotes osteoclast maturation by regulating branched chain amino acid metabolism", Exp. Mol. Med, 54, pp.825~833 (2022)
  140. Ozaki, K., "The L-type amino acid transporter LAT1 inhibits osteoclasto genesis and maintains bone homeostasis through the mTORC1 pathway", Sci. Signal, 12, pp.eaaw3921~ (2019)
  141. Lee, S. H., "The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation", J. Biol. Chem, 283, pp.11526~11534 (2008)
  142. Uehara, S., "Protein kinase N3 promotes bone resorption by osteoclasts in response to Wnt5a-Ror2 signaling", Sci. Signal, 10, pp.eaan0023~ (2017)
  143. Uehara, S., "Inhibitor of protein kinase N3 suppresses excessive bone resorption in ovariectomized mice", J. Bone Min. Metab, 40, pp.251~261 (2022)
  144. Kim, H., "Protocadherin-7 contributes to maintenance of bone homeostasis through regulation of osteoclast multinucleation", Bmb Rep, 53, pp.472~477 (2020)
  145. Kim, H., "PP2A-Mediated GSK3β Dephosphorylation Is Required for Protocadherin-7-dependent regulation of small GTPase RhoA in Osteoclasts", Cells, 12, pp.1967~ (2023)
  146. Mukai, H., "PKN3 is the major regulator of angiogenesis and tumor metastasis in mice", Sci. Rep, 6, pp.18979~ (2016)
  147. Liu, M., "PCDH7 as the key gene related to the co-occurrence of sarcopenia and osteoporosis", Front. Genet, 14, pp.1163162~ (2023)

관련 논문AI추천

Regulation of NFATc1 in Osteoclast Differentiation김낙성, 김정하대한골대사학회 · 대한골대사학회지2014 · 제21권 제4호Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis강영모, 정연관, 한승우대한면역학회 · Immune Network2019 · 제19권 제1호Origin of Osteoclasts: Osteoclast Precursor CellsAndrew J. Suh, Jefferson Tsai, Kaichi Kaneko, Kyung-Hyun Park-Min, Richard Bockman대한골대사학회 · 대한골대사학회지2023 · 제30권 제2호Negative regulators in RANKL-induced osteoclastogenesis김갑순, 김낙성, 이준원대한구강생물학회 · International Journal of Oral Biology2007 · 제32권 제1호Regulation of Osteoclast Differentiation by Cytokine Networks김수미, 김현종, 노재랑, 윤형석, 이나리, Dulshara Sachini Amarasekara대한면역학회 · Immune Network2018 · 제18권 제1호The Role of Toll-Like Receptors in OsteoclastogenesisMijung Yim대한골대사학회 · 대한골대사학회지2020 · 제27권 제4호

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기